Inhibition of Platelet Aggregation by Dialysable Fibrinogen Degradation Products (FDP)

Jolanta Stachurska; Z Latałło; Maria Kopeć

doi:10.1055/s-0038-1654123

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 1970; 23(01): 091-098
DOI: 10.1055/s-0038-1654123

Originalarbeiten – Original Articles – Travaux Originaux

Schattauer GmbH

Inhibition of Platelet Aggregation by Dialysable Fibrinogen Degradation Products (FDP)

Jolanta Stachurska

¹Department of Biochemistry, Institute of Rheumatology, and from the Department of Radiobiology and Health Protection, Institute of Nuclear Research, Warsaw

,

Z Latałło

¹Department of Biochemistry, Institute of Rheumatology, and from the Department of Radiobiology and Health Protection, Institute of Nuclear Research, Warsaw

,

Maria Kopeć

¹Department of Biochemistry, Institute of Rheumatology, and from the Department of Radiobiology and Health Protection, Institute of Nuclear Research, Warsaw

› Institutsangaben

Abstract

Summary

During prolonged proteolysis of fibrinogen by plasmin dialysable, low molecular fragments accumulate which inhibit platelet aggregation induced by thrombin, ADP, adrenaline and noradrenaline. These fragments isolated by dialysis were separated on sephadex G-25 column. The active component has probably a molecular weight lower than 5,000 and does not contain aromatic amino acids.

Volltext

Referenzen

References
1 Barnhart M. J, Cress D. C, Henry R. L, Riddle J. M. Influence of fibrinogen split products on platelets. Thrombos. Diathes. haemorrh. (Stuttg.) 17: 78 1967;
2 Booyse M, Rafelson Jr. M. Studies on human platelets III. A contractile protein model for platelet aggregation. Blood 33: 100 1969;
3 Buluk K, Malofiejew M, Czokalo M. Unknown properties of the products of plasmin degradation of fibrinogen and fibrin. Bull. Acad. Pol. Sci Cl VI 14: 193 1966;
4 Chambers D. A, Salzman E. W, Neri L. L. Characterization of ecto ATP-ase of human blood platelets. Arch. Biochem 119: 173 1967;
5 Cronberg S. Effect of fibrinolysis on adhesion and aggregation of human platelets. Thrombos. Diathes. haemorrh. (Stuttg.) 19: 474 1968;
6 Hagan J. J, Ablondi F. B, Benso E. C. Purification and biochemical properties of human plasminogen. J. biol. Chem 235: 1005 1960;
7 Jerushalmy Z, Zucker M. Some effects of fibrinogen degradation products (FDP) on blood platelets. Thrombos. Diathes. haemorrh. (Stuttg.) 15: 413 1965;
8 Kekwick R. A, Mackay M. E, Nance M. H, Record B. R. The purification of human fibrinogen. Biochem. J 60: 671 1965;
9 Kline D. L. The purification and cristallization of plasminogen (Profibrinolysin). J. biol. Chem 204: 949 1953;
10 Kopeć M, Budzyński A. Z, Latałło Z. S, Lipiński B, Stachurska J, Węgrzynowicz Z, Kowalski E. Interaction of platelet and fibrinogen degradation products in hemostasis. In Kowalski E, and Niewiarowski S. (Eds.) Biochemistry of blood platelets. 147 Academic Press; London/New York PWN: Polish Scientific Publishers, Warszawa 1967
11 Kopeć M, Budzyński A. Z, Stachurska J, Węgrzynowicz Z, Kowalski E. Studies on the mechanism of interference of fibrinogen degradation products (FDP) with the platelet function. Role of fibrinogen in the platelet atmosphere. Thrombos. Diathes. haemorrh. (Stuttg.) 25: 476 1966;
12 Kowalski E, Budzyński A. Z, Kopeć M, Latałło Z. S, Lipiński B, Węgrzynowicz Z. Studies on the molecular pathology and pathogenesis of bleeding in severe fibrinolytic states in dogs. Thrombos. Diathes. haemorrh. (Stuttg.) 12: 69 1964;
13 Kowalski E, Kopeć M, Węgrzynowicz Z. Influence of fibrinogen degradation products (FDP) on platelet aggregation, adhesiveness and viscous metamorphosis. Thrombos. Diathes. haemorrh. (Stuttg.) 10: 406 1964;
14 Larrieu M. J, Inceman S, Marder V. Action des produits de degradation du fibrinogene sur les fonctions plaquettaires. Nouv. Rev. franç. Hémat 7: 691 1967;
15 Larrieu M. J, Marder V. J, Inceman S. Effects of fibrinogen degradation products on platelets and coagulation. In Koller F, and Streuli F. (Eds.) Diffuse intravascular clotting. Trans. Int. Comm. on Haemostasis and Thrombosis, 1965. 215 Schattauer; Stuttgart: 1966
16 Lüscher E. F. Biochemistry of viscous metamorphosis and retraction. Exp. Biol. Med 3: 112 1968;
17 Nachman R. L. A, Marcus J, Softer L. B. Platelet thrombosthenin subcellular location and function. J. clin. Invest 46: 1380 1967;
18 Osbahr A. J, Gladner J. A, Laki K. Studies on the physiological activity of the peptide released during the fibrinogen-fibrin conversion. Biochim. biophys. Acta (Amst.) 86: 535 1964;
19 Paliwoda H, Lui J, Wolf R, Christi H. L. Über den Einfluß von Fibrinogenspaltprodukten auf die Entstehung plättchenreicher Abscheidungsthromben. Thrombos. Diathes. haemorrh. (Stuttg.) 19: 540 1968;
20 Prentice C. R. H, Turpic A. G. G, Hassanein A. A, McNicol G. P. Changes in platelet behaviour during arvin therapy. Lancet I: 644 1969;
21 Salzman E. W, Chambers D. A, Neri L. L. Mechanism of inhibition of ADP induced platelet aggregation by diguanidino compounds. Fed. Proc 25: 554 1966;
22 Thomas D. P, Rean V. J, Stuart R. K. Platelet aggregation in patients with Laennec’s cirrhosis of the liver. New Engl. J. Med 276: 1344 1967;